191 related articles for article (PubMed ID: 27666584)
1. Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
Emmanuel B; Sidique N; Zhang X; Poonia B; Sneller MC; Kottilil S
J Viral Hepat; 2017 Feb; 24(2):128-131. PubMed ID: 27666584
[TBL] [Abstract][Full Text] [Related]
2. Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis.
Mathur P; Emmanuel B; Sneller M; Zhang X; Poonia B; Kottilil S
J Med Virol; 2018 May; 90(5):936-941. PubMed ID: 29236302
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Delluc A; Piette JC; Cacoub P
Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
[TBL] [Abstract][Full Text] [Related]
4. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.
Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P
Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291
[TBL] [Abstract][Full Text] [Related]
5. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report.
Massari M; Catania A; Magnani G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216
[No Abstract] [Full Text] [Related]
7. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
[TBL] [Abstract][Full Text] [Related]
8. The dilemma of treating hepatitis C virus-associated cryoglobulinemia.
Roccatello D; Fenoglio R; Sciascia S
Curr Opin Rheumatol; 2019 Sep; 31(5):499-504. PubMed ID: 31090590
[TBL] [Abstract][Full Text] [Related]
9. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.
Sneller MC; Hu Z; Langford CA
Arthritis Rheum; 2012 Mar; 64(3):835-42. PubMed ID: 22147444
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study.
Saadoun D; Ghembaza A; Riviere S; Mekinian A; Boutemy J; Leroux G; Domont F; Maillard H; Vautier M; Cacoub P
J Autoimmun; 2021 Jan; 116():102577. PubMed ID: 33248866
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus-related cryoglobulinemic vasculitis.
Mazzaro C; Mauro E; Ermacora A; Doretto P; Fumagalli S; Tonizzo M; Toffolutti F; Gattei V
Minerva Med; 2021 Apr; 112(2):175-187. PubMed ID: 33198444
[TBL] [Abstract][Full Text] [Related]
13. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.
Colantuono S; Mitrevski M; Yang B; Tola J; Carlesimo M; De Sanctis GM; Fiorilli M; Casato M; Visentini M
Clin Rheumatol; 2017 Mar; 36(3):617-623. PubMed ID: 28111716
[TBL] [Abstract][Full Text] [Related]
15. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
[TBL] [Abstract][Full Text] [Related]
16. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.
Dammacco F; Lauletta G; Vacca A
Clin Exp Med; 2023 Jun; 23(2):255-272. PubMed ID: 35348938
[TBL] [Abstract][Full Text] [Related]
17. B-cell depletion in the treatment of mixed cryoglobulinemia.
Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy.
Quartuccio L; Isola M; Masolini P; Scaini P; Zani R; Tavoni A; Pietrogrande M; Bombardieri S; De Vita S
Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S9-14. PubMed ID: 23044040
[TBL] [Abstract][Full Text] [Related]
19. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.
Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S
Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
